Donate Toggle Menu

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell carcinoma (RCC).

Media Contact

Email Radha Chitale with media inquiries. Please include your name, outlet, topic, deadline, and contact details.